These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28922805)

  • 21. Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses.
    Chapagain M; Pasipanodya JG; Athale S; Bernal C; Trammell R; Howe D; Gumbo T
    J Antimicrob Chemother; 2022 May; 77(6):1694-1705. PubMed ID: 35257162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease.
    Deshpande D; Pasipanodya JG; Gumbo T
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2157-63. PubMed ID: 26810646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease.
    Adachi Y; Tsuyuguchi K; Kobayashi T; Kurahara Y; Yoshida S; Kagawa T; Hayashi S; Suzuki K
    J Infect Chemother; 2020 Jul; 26(7):676-680. PubMed ID: 32171660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice.
    Bermudez LE; Nash K; Petrofsky M; Young LS; Inderlied CB
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2619-22. PubMed ID: 10991834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients.
    Griffith DE; Brown BA; Murphy DT; Girard WM; Couch L; Wallace RJ
    J Infect Dis; 1998 Jul; 178(1):121-6. PubMed ID: 9652431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent.
    Deshpande D; Srivastava S; Chapagain ML; Lee PS; Cirrincione KN; Pasipanodya JG; Gumbo T
    J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i36-i42. PubMed ID: 28922808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.
    Deshpande D; Srivastava S; Meek C; Leff R; Gumbo T
    Antimicrob Agents Chemother; 2010 May; 54(5):1728-33. PubMed ID: 20231389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.
    Kadota T; Matsui H; Hirose T; Suzuki J; Saito M; Akaba T; Kobayashi K; Akashi S; Kawashima M; Tamura A; Nagai H; Akagawa S; Kobayashi N; Ohta K
    BMC Infect Dis; 2016 Jan; 16():31. PubMed ID: 26818764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study.
    Miwa S; Shirai M; Toyoshima M; Shirai T; Yasuda K; Yokomura K; Yamada T; Masuda M; Inui N; Chida K; Suda T; Hayakawa H
    Ann Am Thorac Soc; 2014 Jan; 11(1):23-9. PubMed ID: 24298907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease.
    Griffith DE; Brown BA; Girard WM; Griffith BE; Couch LA; Wallace RJ
    Clin Infect Dis; 2001 Jun; 32(11):1547-53. PubMed ID: 11340525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages.
    Pellegrin I; Maugein J; Lapeyre C; Barbeau P; Leng B; Pellegrin JL
    J Antimicrob Chemother; 1996 Mar; 37(3):501-10. PubMed ID: 9182107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.
    Moon SM; Park HY; Kim SY; Jhun BW; Lee H; Jeon K; Kim DH; Huh HJ; Ki CS; Lee NY; Kim HK; Choi YS; Kim J; Lee SH; Kim CK; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6758-6765. PubMed ID: 27572413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A survey of clarithromycin monotherapy and long-term administration of ethambutol for patients with MAC lung disease in Japan: A retrospective cohort study using the database of health insurance claims.
    Iwao T; Kato G; Ito I; Aramaki E; Kuroda T
    Pharmacoepidemiol Drug Saf; 2020 Apr; 29(4):427-432. PubMed ID: 31876044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low rates of macrolide-resistant Mycobacterium avium complex in cystic fibrosis despite chronic azithromycin therapy.
    Richter WJ; Nguyen JA; Wu AE; Jennings MT; Lechtzin N; Parrish NM; Psoter KJ; Cohen KA
    J Cyst Fibros; 2021 May; 20(3):555-557. PubMed ID: 32950412
    [No Abstract]   [Full Text] [Related]  

  • 35. Mycobacterium avium complex pulmonary disease: management options in HIV-negative patients.
    Ramirez J; Mason C; Ali J; Lopez FA
    J La State Med Soc; 2008; 160(5):248-54; quiz 254, 293. PubMed ID: 19048978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and treatment of infections due to Mycobacterium avium complex.
    Kasperbauer SH; Daley CL
    Semin Respir Crit Care Med; 2008 Oct; 29(5):569-76. PubMed ID: 18810690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium.
    Deshpande D; Gumbo T
    Future Microbiol; 2011 Apr; 6(4):433-9. PubMed ID: 21526944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus.
    Dunne M; Fessel J; Kumar P; Dickenson G; Keiser P; Boulos M; Mogyros M; White AC; Cahn P; O'Connor M; Lewi D; Green S; Tilles J; Hicks C; Bissett J; Schneider MM; Benner R
    Clin Infect Dis; 2000 Nov; 31(5):1245-52. PubMed ID: 11073759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dosage ethambutol, less than 12.5 mg/kg/day, does not worsen the clinical outcomes of pulmonary Mycobacterium avium and Mycobacterium intracellulare disease: a retrospective cohort study.
    Watanabe F; Kaburaki S; Furuuchi K; Uesugi F; Fujiwara K; Tanaka Y; Yoshiyama T; Shiraishi Y; Kurashima A; Ohta K; Hanada K; Morimoto K
    Infection; 2022 Aug; 50(4):879-887. PubMed ID: 35106717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease.
    Tanaka E; Kimoto T; Tsuyuguchi K; Watanabe I; Matsumoto H; Niimi A; Suzuki K; Murayama T; Amitani R; Kuze F
    Am J Respir Crit Care Med; 1999 Sep; 160(3):866-72. PubMed ID: 10471610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.